CoChat

PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells

Open access

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Abstract

Platinum compounds are the foundation of chemotherapy regimens for non-small cell lung cancer (NSCLC) despite poor response rates and limited response duration. It has been reported that tumor expression of excision repair cross-complementation group 1 (ERCC1), a key component in nucleotide excision repair, may correlate with clinical response to platinum agents. We found that most primary lung tumor specimens demonstrated a stronger protein expression of poly (adenosine diphosphate ribose) polymerases 1 (PARP1) than their normal counterparts. Therefore, we hypothesized that combining PARP inhibition with platinum compounds may be an approach to improve platinum-based therapy for NSCLC. Drug combination experiments revealed that two distinct PARP inhibitors, olaparib and veliparib, not only potentiated the cell killing by cisplatin but also conferred cytotoxicity as a single agent specifically in ERCC1-low HCC827 and PC9 but not in ERCC1-high A549 and H157 lung cancer cells. Moreover, small interfering RNA knockdown of ERCC1 in A549 and H157 cells increased their sensitivities to both cisplatin and olaparib in a synergistic manner in our model. Furthermore, mechanistic studies indicated that combined PARP inhibitor and cisplatin could lead to sustained DNA double-strand breaks, prolonged G2/M cell cycle arrest with distinct activation of checkpoint kinase 1 signaling and more pronounced apoptosis preferentially in lung cancer cells with low ERCC1 expression. Collectively, these data suggest that there is a synergistic relationship between PARP inhibition and low ERCC1 expression in NSCLC that could be exploited for novel therapeutic approaches in lung cancer therapy based on tumor ERCC1 expression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/carcin/bgs393

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Research works printed but not linked: 3

  1. KIRSCHNER, 2010, Anticancer Research, 30, 3223
  2. Selvakumaran, 2003, Cancer Research, 63, 1311
  3. Sorenson, 1988, Cancer Research, 48, 6703

Cited by

See all 102

Metadata

Authors
Cheng, H., Zhang, Z., Borczuk, A., Powell, C. A., Balajee, A. S., Lieberman, H. B., & Halmos, B.
Affiliations
  • NewYork–Presbyterian Hospital (US)
  • Mount Sinai Hospital (US)
  • Columbia University Irving Medical Center (US)
Venue
Carcinogenesis
Published
2012-12-28
Volume
34
Issue
4
Pages
739-749
ISSN
  • 0143-3334 (ISSN-L)
  • 1460-2180
OpenAlex
W2135915034
Cited by
99
References
50
Citations by year
2026: 2 · 2025: 5 · 2024: 5 · 2023: 3 · 2022: 8 · 2021: 18 · 2020: 4 · 2019: 10 · 2018: 4 · 2017: 7 · 2016: 7 · 2015: 15 · 2014: 8 · 2013: 3
FWCI
4.12
Type
journal article
Language
en
Open access
Locations
  • Carcinogenesis (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Pfizer
  • National Institutes of Health (5k12ca132783-12)
  • National Cancer Institute (CA 130536, 5K12CA132783-04, R01CA130536)
  • National Institute of General Medical Sciences (R01GM079107, GM079107)
Topics
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
  • Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
Keywords
PARP inhibition, cisplatin, ERCC1, non-small cell lung cancer, olaparib, veliparib, nucleotide excision repair, drug synergy, DNA double-strand breaks, G2/M cell cycle arrest, apoptosis, tumor markers
MeSH terms
Poly(ADP-ribose) Polymerase Inhibitors, Checkpoint Kinase 1, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Benzimidazoles, Carcinoma, Non-Small-Cell Lung, Cisplatin, DNA-Binding Proteins, Drug Synergism, Endonucleases, Humans, Lung Neoplasms, Phthalazines, Piperazines, Poly(ADP-ribose) Polymerases, Protein Kinases, Apoptosis, RNA Interference, RNA, Small Interfering, Cell Line, Tumor, DNA Breaks, Double-Stranded, G2 Phase Cell Cycle Checkpoints

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells. https://app.cochat.ai/papers/10.1093/carcin/bgs393
The paper
Cheng, H., Zhang, Z., Borczuk, A., Powell, C. A., Balajee, A. S., Lieberman, H. B., & Halmos, B. (2013). PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells. Carcinogenesis. https://doi.org/10.1093/carcin/bgs393

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.